GlassScriptPhysician profile
Michael Neira
NPI 1447080148
$3,043.27
in general payments reported to CMS, 2019-2025
14 companies · $3,019 in 2025
The $3,019 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $24.59 · 2025: $3,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223 · Travel and Lodging: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.95 |
| Travel and Lodging | $820.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,140.69 | 2025 | Watchman, Watchman Flx |
| Amgen INC. | $332.60 | 2025 | Repatha |
| Abbott Laboratories | $304.69 | 2025 | Ensite |
| Edwards Lifesciences Corporation | $191.16 | 2025 | Konect Resilia |
| Biomerieux INC | $173.01 | 2025 | |
| Novo Nordisk INC | $157.88 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.97 | 2025 | Jardiance |
| Medtronic, INC. | $131.26 | 2025 | Closurefast |
| Pfizer INC. | $121.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $110.49 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $99.17 | 2024-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $63.70 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.26 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.99 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Neira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.